Literature DB >> 6804113

Propranolol in angina pectoris. Comparison of long-acting and standard-formulation propranolol.

J O Parker, A Porter, J D Parker.   

Abstract

In a double-blind, crossover study in 20 patients with stable angina pectoris, the effects of long-acting propranolol, 160 mg administered once daily for 4 weeks, were compared with those of standard propranolol, 40 mg given four times daily for 4 weeks. The patients suffered no adverse effects when they were switched between treatment schedules. The average number of episodes of angina during the 4 weeks on long-acting propranolol was 7.3 and on standard propranolol. 6.3. Average nitroglycerin consumption was 5.8 and 4.9 tablets during therapy with these two drug programs. The resting values for heart rate, systolic blood pressure and rate-pressure product were similar when determined 25.4 hours after a dose of long-acting propranolol and 10.7 hours after standard propranolol. When the patients exercised at these times, patients on long-acting propranolol and standard propranolol had similar walking times to the onset of angina and to the development of moderate angina. The values for heart rate, systolic blood pressure and rate-pressure product were similar at rest and during exercise during these two treatment programs. We conclude that long-acting propranolol administered in a dose of 160 mg daily is as effective as 50 mg of standard propranolol four times daily.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6804113     DOI: 10.1161/01.cir.65.7.1351

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  5 in total

Review 1.  Beta-adrenergic blockers in systemic hypertension: pharmacokinetic considerations related to the current guidelines.

Authors:  William H Frishman; Mamata Alwarshetty
Journal:  Clin Pharmacokinet       Date:  2002       Impact factor: 6.447

Review 2.  Pharmacokinetic optimisation of therapy with beta-adrenergic blocking agents.

Authors:  W H Frishman; E J Lazar; G Gorodokin
Journal:  Clin Pharmacokinet       Date:  1991-04       Impact factor: 6.447

Review 3.  Pharmacokinetics of long acting propranolol. Implications for therapeutic use.

Authors:  G S Nace; A J Wood
Journal:  Clin Pharmacokinet       Date:  1987-07       Impact factor: 6.447

4.  Pharmacokinetic and pharmacodynamic studies with a new controlled-release formulation of propranolol in normal volunteers: a comparison with other commercially available formulations.

Authors:  E Perucca; R Grimaldi; G Gatti; M Caravaggi; F Crema; S Lecchini; G M Frigo
Journal:  Br J Clin Pharmacol       Date:  1984-07       Impact factor: 4.335

5.  Comparative effects of long-acting and conventional propranolol on stress-induced angina pectoris and on frequency of ventricular premature beats.

Authors:  V Hansteen; K Endresen; H Hellemann; I I Eriksen; O Brorssen; T Ekeli; M Day; N S Baber
Journal:  Br J Clin Pharmacol       Date:  1984-05       Impact factor: 4.335

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.